UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.528

Sortiert nach

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Investigational new drugs, 2014-10, Vol.32 (5), p.825-837

2014

Volltextzugriff (PDF)

Development of artemisinin compounds for cancer treatment

Investigational new drugs, 2013-02, Vol.31 (1), p.230-246

2013

Volltextzugriff (PDF)

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma

Investigational new drugs, 2014-02, Vol.32 (1), p.178-187

2014

Volltextzugriff (PDF)

Ipilimumab associated hepatitis: imaging and clinicopathologic findings

Investigational new drugs, 2013-08, Vol.31 (4), p.1071-1077

2013

Volltextzugriff (PDF)

Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma

Investigational new drugs, 2014-12, Vol.32 (6), p.1246-1257

2014

Volltextzugriff (PDF)

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

Investigational new drugs, 2014-08, Vol.32 (4), p.670-681

2014

Volltextzugriff (PDF)

Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials

Investigational new drugs, 2013-08, Vol.31 (4), p.1087-1094

2013

Volltextzugriff (PDF)

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

Investigational new drugs, 2013-08, Vol.31 (4), p.986-1000

2013

Volltextzugriff (PDF)

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

Investigational new drugs, 2013-08, Vol.31 (4), p.833-844

2013

Volltextzugriff (PDF)

A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors

Investigational new drugs, 2014-06, Vol.32 (3), p.436-444

2014

Volltextzugriff (PDF)

Cytotoxic flavonoids and isoflavonoids from Erythrina sigmoidea towards multi-factorial drug resistant cancer cells

Investigational new drugs, 2014-12, Vol.32 (6), p.1053-1062

2014

Volltextzugriff (PDF)

PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines

Investigational new drugs, 2014-10, Vol.32 (5), p.783-794

2014

Volltextzugriff (PDF)

Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors

Investigational new drugs, 2014-06, Vol.32 (3), p.452-464

2014

Volltextzugriff (PDF)

The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer

Investigational new drugs, 2014-08, Vol.32 (4), p.577-586

2014

Volltextzugriff (PDF)

Kidney injuries related to ipilimumab

Investigational new drugs, 2014-08, Vol.32 (4), p.769-773

2014

Volltextzugriff (PDF)

Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma

Investigational new drugs, 2013-04, Vol.31 (2), p.425-434

2013

Volltextzugriff (PDF)

Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells

Investigational new drugs, 2014-12, Vol.32 (6), p.1096-1104

2014

Volltextzugriff (PDF)

Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation

Investigational new drugs, 2014-08, Vol.32 (4), p.604-617

2014

Volltextzugriff (PDF)

Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors

Investigational new drugs, 2014-12, Vol.32 (6), p.1144-1154

2014

Volltextzugriff (PDF)

A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer

Investigational new drugs, 2014-04, Vol.32 (2), p.355-361

2014

Volltextzugriff (PDF)

Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer

Investigational new drugs, 2014-10, Vol.32 (5), p.904-912

2014

Volltextzugriff (PDF)

Novel antitumour indole alkaloid, Jerantinine A, evokes potent G2/M cell cycle arrest targeting microtubules

Investigational new drugs, 2014-10, Vol.32 (5), p.838-850

2014

Volltextzugriff (PDF)

A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors

Investigational new drugs, 2014-08, Vol.32 (4), p.653-660

2014

Volltextzugriff (PDF)

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology

Investigational new drugs, 2014-10, Vol.32 (5), p.851-859

2014

Volltextzugriff (PDF)

Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery

Investigational new drugs, 2013-08, Vol.31 (4), p.949-958

2013

Volltextzugriff (PDF)

1 – 25 von 1.528

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieCancer Immunology And Immunotherapy

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

Zeitschrift / SerieInvestigational New Drugs

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.528)
Mit Volltextzugriff
(1.528)

Publikationsform

Artikel
(1.528)

Sprache

Japanisch
(115)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Zeitschrift / Serie

Menü

Weitere Dienste

Einstellungen

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Development of artemisinin compounds for cancer treatment

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma

Ipilimumab associated hepatitis: imaging and clinicopathologic findings

Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

Cardiac glycosides in cancer therapy: from preclinical investigations towards clinical trials

First-in-human phase 1/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models

A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors

Cytotoxic flavonoids and isoflavonoids from Erythrina sigmoidea towards multi-factorial drug resistant cancer cells

PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines

Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors

The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer

Kidney injuries related to ipilimumab

Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma

Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells

Oxidative cytotoxic agent withaferin A resensitizes temozolomide-resistant glioblastomas via MGMT depletion and induces apoptosis through Akt/mTOR pathway inhibitory modulation

Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors

A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer

Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer

Novel antitumour indole alkaloid, Jerantinine A, evokes potent G2/M cell cycle arrest targeting microtubules

A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology

Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery

Aktive Filter

Suchergebnisse filtern